MiRNA-based predictive models for diagnosis and prognosis of prostate cancer
AssigneesOhio State Innovation Foundation, University of Freiburg
InventorsArnab Chakravarti, Erica McKenzie Bell, Simon Kirste, Anca-Ligia Grosu
Life of this patent
Estimating the term…
Abstract
The lack of clear predictors of prostate cancer progression leads to subjective decision-making regarding courses of treatment. The identification of new biomarkers that are predictive of recurrence after radical prostatectomy would advance the field of prostate cancer treatment. Disclosed are miRNAs that can be used as molecular biomarkers to detect or predict the progression of prostate cancer and to adjust a treatment plan accordingly. Furthermore, kits are included for the detection of these miRNAs.
Claims7
A method for treating a subject based on a high biochemical recurrence risk score following post-prostatectomy salvage radiation therapy, comprising
- a) determining a miRNA expression profile from a sample from the subject of at least 1 miRNA selected from the group consisting of hsa-miR-628-3p, hsa-miR-1193, hsa-miR-601, hsa-miR-4516, hsa-miR-320e, hsa-miR-508-3p, hsa-miR-598, hsa-miR-626, hsa-miR-563;
- and
- b) calculating a-miRNA-based recurrence risk score from the miRNA expression profile;
- wherein a high recurrence risk score when compared to Gleason score and lymph node status alone, wherein a high recurrence risk score is based on a regression value of about 0.5 or greater, is an indication of biochemical recurrence within 1 to 5 years;
- and
- c) treating the subject with a high recurrence risk score with adjuvant therapy, radiation therapy, palliative care, or a combination thereof.
Dependencies are inferred from the claim text.